Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Concurrent use of nucleoside reverse transcriptase inhibitors and purine analogs is associated with worse survival for patients with myeloid neoplasms: A single-center retrospective analysis

Jason Gilbert, Megan Othus, Suravi Raychaudhuri, Katie Russell, Carole Shaw, Rutu Vyas, Anna Halpern, Paul Hendrie, Raya Mawad, Cristina Maria Ghiuzeli, Ryan Cassaday, Roland Walter, Emily Ford, Jacob Appelbaum, Mary-Elizabeth Percival

Blood (2025) 146 (Supplement 1): 1677.

https://doi.org/10.1182/blood-2025-1677

Published: 2025

Journal Articles

A randomized phase 2 trial of CPX-351 vs. CLAG-m (Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone) in medically less-fit adults with previously untreated acute myeloid leukemia (AML) or other high-grade myeloid neoplasms

Anna Halpern, Megan Othus, Mary-Elizabeth Percival, Cristina Maria Ghiuzeli, Jacob Appelbaum, Paul Hendrie, Ryan Cassaday, Bart Scott, Jason Cooper, Sioban Keel, Vivian Oehler, Johnnie Orozco, Katie Russell, Raya Mawad, Roland Walter

Blood (2025) 146 (Supplement 1): 1663.

https://doi.org/10.1182/blood-2025-1663

Published: 2025

Journal Articles

A single center review of secondary hemophagocytic lymphohistiocytosis treatment and outcomes.

Brenda Castillo, Aaron Boothby, Sarah Monsell, Paul Hendrie, Prakash Vishnu

Blood (2025) 146 (Supplement 1): 6548.

https://doi.org/10.1182/blood-2025-6548

Published: 2025

Journal Articles

Fractionated gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) based induction chemotherapy is safe and highly effective for newly diagnosed favorable risk AML.

Brenda Castillo, Jacob Appelbaum, Megan Othus, Katie Russell, Rutu Vyas, Paul Hendrie, Anna Halpern, Cristina Maria Ghiuzeli, Ryan Cassaday, Raya Mawad, Mary-Elizabeth Percival, Roland Walter

Blood (2025) 146 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2025-3378

Published: 2025

Journal Articles

Treatment intensity and transplant independently predict survival in TP53-mutated myeloid neoplasms: A large retrospective cohort study of clinical and genomic factors

Sarah Peterson, Megan Othus, Katie Russell, Carole Shaw, Rutu Vyas, Anna Halpern, Cristina Maria Ghiuzeli, Paul Hendrie, Ryan Cassaday, Raya Mawad, Roland Walter, Jacob Appelbaum, Mary-Elizabeth Percival

Blood (2025) 146 (Supplement 1): 5265.

https://doi.org/10.1182/blood-2025-5265

Published: 2025

Journal Articles

Clinical features and outcomes of acquired versus baseline TP53 mutations in myeloid neoplasms: A single-center retrospective analysis

Blood (2025) 146 (Supplement 1): 7022.

https://doi.org/10.1182/blood-2025-7022

Published: 2025

Journal Articles

Pivekimab sunirinine (PVEK) combined with FLAG-IDA for medically fit adults with untreated adverse-risk Acute Myeloid Leukemia (AML) or other high-grade myeloid neoplasms (NCT06034470)

Jacob Appelbaum, Suravi Raychaudhuri, Katie Russell, Kimberly Cadiz, Stacey Fuller, Anna Halpern, Cristina Maria Ghiuzeli, Raya Mawad, Vivian Oehler, Ryan Cassaday, Jason Cooper, Paul Hendrie, Megan Othus, Mary-Elizabeth Percival, Roland Walter

Blood (2025) 146 (Supplement 1): 3422.

https://doi.org/10.1182/blood-2025-3422

Published: 2025

Journal Articles

Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) yields durable remissions and survival in adults with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL): Long-term follow-up of a prospective trial

Mitin Nachu, Philip Stevenson, Kim Quach, Christen Martino, Mary-Elizabeth Percival, Anna Halpern, Pamela Becker, Vivian Oehler, Jason P. Cooper, Johnnie Orozco, Paul Hendrie, Roland Walter, Cristina Maria Ghiuzeli, Raya Mawad, Ryan Cassaday

Blood (2025) 146 (Supplement 1): 5128.

https://doi.org/10.1182/blood-2025-5128

Published: 2025

Journal Articles

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Blood (2020) 135 (22): 1929–1945.

https://doi.org/10.1182/blood.2019003507

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Concurrent use of nucleoside reverse transcriptase inhibitors and purine analogs is associated with worse survival for patients with myeloid neoplasms: A single-center retrospective analysis

A randomized phase 2 trial of CPX-351 vs. CLAG-m (Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone) in medically less-fit adults with previously untreated acute myeloid leukemia (AML) or other high-grade myeloid neoplasms

A single center review of secondary hemophagocytic lymphohistiocytosis treatment and outcomes.

Fractionated gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) based induction chemotherapy is safe and highly effective for newly diagnosed favorable risk AML.

Treatment intensity and transplant independently predict survival in TP53-mutated myeloid neoplasms: A large retrospective cohort study of clinical and genomic factors

Clinical features and outcomes of acquired versus baseline TP53 mutations in myeloid neoplasms: A single-center retrospective analysis

Pivekimab sunirinine (PVEK) combined with FLAG-IDA for medically fit adults with untreated adverse-risk Acute Myeloid Leukemia (AML) or other high-grade myeloid neoplasms (NCT06034470)

Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) yields durable remissions and survival in adults with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL): Long-term follow-up of a prospective trial

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only